Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be…
December 04, 2025 22:03 ET | Source: Protara Therapeutics NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing…
December 04, 2025 07:00 ET | Source: Vaxil Bio Ltd. Not for distribution by US newswire or in United States…
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from…